Epo Biomarkers Market is increasingly gaining rapid traction with rising cases of cancer and ESRD in the U.S.

 

Epo Biomarkers Market

Erythropoietin (Epo) protein is a naturally occurring hormone that can be found in the egg and in various other animal species. This hormone has been proven to increase red blood cell production. This is a very powerful growth factor and has shown promise in many areas of medical research. One of the key reasons for the increased adoption of EPO biomarkers is rising prevalence of end-stage renal disorders (ESRD). In fact, in 2017, there were around 124,500 new cases of registered ESRD as per the U.S. Renal Data System 2019 Annual Data Report. Such a high proportion of cases has necessitated the adoption of epo biomarkers for the diagnosis of ESRD. Furthermore, epo biomarkers can aid in the early detection of the disease, thereby making the treatment more effective and efficient. Hence, such factors can stimulate growth of the epo biomarkers market.

Erythropoietin proteins are used in many medical applications and are useful for many years to come. It is a natural protein that can be found in the body and it can be used by both the body and by doctors to detect iron deficiency anemia. In fact, this is a popular and successful technology used today in the field of genetic medicine. Other major factors that have led to the high adoption of epo biomarkers are increasing launch of erythropoietin alfa for cancer patients who are suffering from anemia. Recently, in May 2018, the U.S. Food and Drug Administration (FDA) approved Retacrit as a biosimilar to Epogen/Procrit for the treatment of anemia caused by chronic kidney disease, use of zidovudine, or chemotherapy. Thus, these factors can augment growth of the epo biomarkers market in the near future.

As far as the regional footprint is concerned, North America region seems to be gaining robust traction in the epo biomarkers market. This is typically due to the fact there is a high prevalence of cancer and the presence of robust healthcare infrastructure. As per the National Cancer Institute, in 2020, around 1,806,590 new cases of cancer were expected to be diagnosed in the U.S. with around 606,520 deaths. On the contrary, Asia Pacific is exhibiting promising signs since there is a presence of key market players such as Shandong Kexing Bioproducts Co. Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., and 3Sbio Group. 

One of the most exciting areas of research with respect to erythropoietin biomarkers is for the treatment and prevention of renal diseases. Preventing and treating renal diseases is one of the biggest challenges for scientists. Regardless of its advantages, epo biomarkers do have certain shortcomings that could limit their adoption. The overproduction of red blood cells due to over-expressions of epo biomarkers can lead to absolute polycythemia. Thus, such conditions can potentially impede growth of the epo biomarkers market in the near future.


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The market for ureteral stents would benefit from the rising prevalence of urological diseases

Increased Prevalence of Chronic Diseases and Stem Cell Therapy R&D to Drive Stem Cell Assay Market Growth